Market closedNon-fractionalADR
BioLineRx/BLRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About BioLineRx
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Ticker
BLRX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Modiin, Israel
Employees
79
Website
www.biolinerx.com
BioLineRx Metrics
BasicAdvanced
$58M
Market cap
-
P/E ratio
-$0.76
EPS
1.54
Beta
-
Dividend rate
Price and volume
Market cap
$58M
Beta
1.54
52-week high
$2.53
52-week low
$0.55
Average daily volume
9.3
Financial strength
Current ratio
1.138
Quick ratio
1.046
Long term debt to equity
54.877
Total debt to equity
86.631
Interest coverage (TTM)
-519.43%
Management effectiveness
Return on assets (TTM)
-81.75%
Return on equity (TTM)
-188.40%
Return on investment (TTM)
-127.94%
Valuation
Price to revenue (TTM)
5.014
Price to book
4.136
Growth
Earnings per share change (TTM)
-30.32%
What the Analysts think about BioLineRx
Analyst Ratings
Majority rating from 1 analysts.
BioLineRx Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$6.8M
41.67%
Net income
-$600K
-95.65%
Profit margin
-8.82%
-96.93%
BioLineRx Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.15
-$0.30
-$0.30
-$0.15
-
Expected
-$0.17
-$0.13
-$0.26
-$0.17
-$0.29
Surprise
-11.76%
130.77%
15.38%
-9.09%
-
BioLineRx News
AllArticlesVideos
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
PRNewsWire·2 months ago
BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
PRNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioLineRx stock?
BioLineRx (BLRX) has a market cap of $58M as of July 27, 2024.
What is the P/E ratio for BioLineRx stock?
The price to earnings (P/E) ratio for BioLineRx (BLRX) stock is 0 as of July 27, 2024.
Does BioLineRx stock pay dividends?
No, BioLineRx (BLRX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next BioLineRx dividend payment date?
BioLineRx (BLRX) stock does not pay dividends to its shareholders.
What is the beta indicator for BioLineRx?
BioLineRx (BLRX) has a beta rating of 1.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell BioLineRx stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.